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EDITORIAL

Peripartum anxiety: parsing heterogeneity in clinical
settings
Verinder Sharma1,20 0 -0 0 -0 0 -0 0
1
Department of Psychiatry and Department of Obstetrics and Gynecology, Western University, London, ON, Canada. 2Parkwood Institute
Mental Health Care Building, London, ON, Canada.

A recent meta-analysis estimated that 20.7 % of women
have one or more anxiety disorders during pregnancy or
in the postpartum period.1 Another meta-analysis reported
that an estimated 8.5% of postpartum women have one or
more anxiety disorders.2 In spite of its common occurrence, the detection and diagnosis of peripartum anxiety
disorders can be challenging for several reasons. Assessing anxiety requires consideration of several core anxiety
and related disorders. Anxiety disorders are usually
accompanied by other psychiatric disorders, particularly
major depression. Consequently, anxiety in clinical settings may be considered a symptom of major depressive
disorder rather than a co-occurring disorder. Finally, a lack
of comprehensive screening may lead to underdiagnosis
and sub-optimal treatment of anxiety disorders. This editorial discusses the heterogeneity of peripartum anxiety
followed by suggestions for its screening, diagnosis and
treatment.
As shown in Box 1, anxiety can occur in the context of
core disorders such as panic disorder, agoraphobia,
generalized anxiety disorder, social phobia, or specific
phobia. Anxiety can also be a manifestation of related
disorders, such as obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder, or illness
anxiety disorder. Anxiety can accompany major depressive disorder or bipolar disorder in the form of anxious
distress. Comorbidity with other anxiety or related disorders is also common. For example, approximately 90%
of women with childbirth-related post-traumatic disorder
have postpartum depression, and 31% of women with
postpartum depression have childbirth-related post-traumatic stress disorder.3 Another study found that approximately 70% of women who screened positive for
obsessive-compulsive disorder also screened positive for
postpartum depression.4
Peripartum anxiety generally occurs in the context of a
pre-existing psychiatric disorder. However, first onset of
obsessive-compulsive disorder is not uncommon. Pregnancy appears to be a specific trigger for the onset or
exacerbation of obsessive-compulsive disorder or panic
disorder. Despite its common occurrence during or

after pregnancy, obsessive-compulsive disorder may be
frequently underdiagnosed or misdiagnosed. Due to the
distressing nature of obsessive thoughts or images,
women may feel uncomfortable or ashamed about reporting these symptoms. Illness anxiety disorder, a related
somatic symptom disorder, is considered a variant of
obsessive-compulsive disorder by some researchers. It
manifests in the form of anxiety about acquiring or having a
serious physical illness. We have recently reported that
various reproductive events, including pregnancy and the
postpartum period, are associated with increased risk of
onset or exacerbation of illness anxiety disorder. Unless
asked specifically about the source of anxiety, women do
not generally disclose their fears about serious physical
illness. Tokophobia, described as an irrational fear and
avoidance of childbirth in spite of desperately wanting a
child, is common, particularly in nulliparous women.
A study with a primarily female sample found that 78%
of patients with major depressive disorder met the DSM-5
criteria for anxious distress specifier. Symptoms of anxious distress, such as feeling tense, restlessness, and a
feeling that something bad will happen, may be particularly common in the peripartum population.5 The clinical
significance of the specifier lies in its association with a
more severe course of illness, worse outcomes, and an
increased risk of self-harm.
Women are generally not screened for anxiety during or
after pregnancy. Among the screening instruments, there
is considerable variation regarding the assessed constructs. Some studies have focused on identifying general
anxiety, others on pregnancy-related anxiety, and yet
others on specific anxiety disorders. Only a few studies
have validated the performance of scales against a
structured diagnostic interview. The National Institute for
Health and Care Excellence guidelines on perinatal
mental health recommend using the 2-item Generalized
Anxiety Disorder scale (GAD-2) for screening in pregnant
or postpartum women. The GAD-2, a reasonable option
for screening in the general population, has a sensitivity of
86% and specificity of 83% using a cut-off score of 3.
However, there are scant data on its use in the perinatal
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Box 1 DSM-5 core anxiety and related disorders during pregnancy and postpartum
Core anxiety disordersw

Panic disorder, agoraphobia, generalized anxiety disorder, social phobia and specific phobia

Related disorders

Bipolar I or II disorders with anxious distress, major depressive disorder with anxious distress,
obsessive-compulsive disorder, posttraumatic stress disorder, acute stress disorder and illness anxiety disorder

w

Excluding substance/medication-induced anxiety disorder and anxiety disorder due to another medical condition.

population. Moreover, a recent study concluded that
neither the GAD-2 nor the Edinburgh Postnatal Depression
Scale can be recommended for widespread screening of
peripartum anxiety. In general, screening tools that assess
core anxiety and related disorders should be preferred over
measures of general anxiety.
Women with a severe anxiety disorder, comorbid anxiety and depression, or those at risk of harming themselves or the newborn should be referred for psychiatric
evaluation and follow-up. Assessment should include
exploration of anxiety symptoms (anxious distress), anxiety disorders, and common comorbidities, such as mood
disorders or substance use disorder. Women should be
specifically asked about the symptoms of obsessivecompulsive disorder or illness anxiety disorder. An organic cause of anxiety should be suspected when the patient
has signs or symptoms suggestive of preeclampsia,
hyperthyroidism, or substance use/abuse or withdrawal.
Suicide risk assessment should be an integral part of the
evaluation of women with anxiety, particularly those with
comorbid mood disorders.
Correct diagnosis of constituent disorders is a prerequisite to proper management of peripartum anxiety.
Treatment strategies should target the underlying psychiatric disorder rather than manage anxiety symptoms.
Drug treatment is indicated for cases of severe anxiety or
for those with anxiety and comorbid depression. Antidepressants should be avoided in women with anxiety
and comorbid bipolar depression, and preference should
be given to mood stabilizers such as lamotrigine or
quetiapine. Since first trimester-exposure to benzodiazepines can increase the risk of cleft lip and palate, these
drugs should be avoided; however, a brief trial (less than

two weeks) of a benzodiazepine may be considered in
women with severe anxiety.
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